000284766 001__ 284766
000284766 005__ 20240229155055.0
000284766 0247_ $$2doi$$a10.3390/ijms241914890
000284766 0247_ $$2pmid$$apmid:37834336
000284766 0247_ $$2pmc$$apmc:PMC10573523
000284766 0247_ $$2ISSN$$a1422-0067
000284766 0247_ $$2ISSN$$a1661-6596
000284766 037__ $$aDKFZ-2023-02077
000284766 041__ $$aEnglish
000284766 082__ $$a540
000284766 1001_ $$aKoukourakis, Ioannis M$$b0
000284766 245__ $$aProstate Cancer Stem Cells: Biology and Treatment Implications.
000284766 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2023
000284766 3367_ $$2DRIVER$$aarticle
000284766 3367_ $$2DataCite$$aOutput Types/Journal article
000284766 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1697525231_8574$$xReview Article
000284766 3367_ $$2BibTeX$$aARTICLE
000284766 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284766 3367_ $$00$$2EndNote$$aJournal Article
000284766 520__ $$aStem cells differentiate into mature organ/tissue-specific cells at a steady pace under normal conditions, but their growth can be accelerated during the process of tissue healing or in the context of certain diseases. It is postulated that the proliferation and growth of carcinomas are sustained by the presence of a vital cellular compartment resembling stem cells residing in normal tissues: 'stem-like cancer cells' or cancer stem cells (CSCs). Mutations in prostate stem cells can lead to the formation of prostate cancer. Prostate CSCs (PCSCs) have been identified and partially characterized. These express surface markers include CD44, CD133, integrin α2β1, and pluripotency factors like OCT4, NANOG, and SOX2. Several signaling pathways are also over-activated, including Notch, PTEN/Akt/PI3K, RAS-RAF-MEK-ERK and HH. Moreover, PCSCs appear to induce resistance to radiotherapy and chemotherapy, while their presence has been linked to aggressive cancer behavior and higher relapse rates. The development of treatment policies to target PCSCs in tumors is appealing as radiotherapy and chemotherapy, through cancer cell killing, trigger tumor repopulation via activated stem cells. Thus, blocking this reactive stem cell mobilization may facilitate a positive outcome through cytotoxic treatment.
000284766 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000284766 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000284766 650_7 $$2Other$$achemotherapy
000284766 650_7 $$2Other$$aprostate cancer
000284766 650_7 $$2Other$$aradiotherapy
000284766 650_7 $$2Other$$astem cells
000284766 7001_ $$00000-0003-2977-7895$$aPlatoni, Kalliopi$$b1
000284766 7001_ $$aKouloulias, Vassilis$$b2
000284766 7001_ $$0P:(DE-He78)fa2079aae8ff5ea85fc4fc1504e5a730$$aArelaki, Stella$$b3$$udkfz
000284766 7001_ $$aZygogianni, Anna$$b4
000284766 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms241914890$$gVol. 24, no. 19, p. 14890 -$$n19$$p14890$$tInternational journal of molecular sciences$$v24$$x1422-0067$$y2023
000284766 909CO $$ooai:inrepo02.dkfz.de:284766$$pVDB
000284766 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2022$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:31:47Z
000284766 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:31:47Z
000284766 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-07T16:31:47Z
000284766 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-07T16:31:47Z
000284766 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2022$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
000284766 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
000284766 9141_ $$y2023
000284766 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fa2079aae8ff5ea85fc4fc1504e5a730$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000284766 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000284766 9201_ $$0I:(DE-He78)B280-20160331$$kB280$$lB280 Translationale funktionelle Krebsgenomik$$x0
000284766 980__ $$ajournal
000284766 980__ $$aVDB
000284766 980__ $$aI:(DE-He78)B280-20160331
000284766 980__ $$aUNRESTRICTED